$32.79
+2.1%Harmony Biosciences Holdings, Inc., a commercial-stage pharmaceutical company, develops and commercializes therapies for patients with rare neurological disorders in the United States. Its product, WAKIX is a medication for the treatment of excessive daytime sleepiness in adult patients with narcolepsy. The company was formerly known as Harmony Biosciences II, Inc. and changed its name to Harmony Biosciences Holdings, Inc. in February 2020. Harmony Biosciences Holdings, Inc. was incorporated in 2017 and is based in Plymouth Meeting, Pennsylvania.
Last Annual Value
96.79M
3-Year CAGR
21%
5-Year CAGR
34%
10-Year CAGR
%
| Company | Net Receivables | CAGR 3Y | CAGR 5Y | CAGR 10Y | |
|---|---|---|---|---|---|
![]() Harmony Biosciences Holdings, Inc. NASDAQ:HRMY | 96.79M | 9.3% | 22.7% | N/A | |
![]() MannKind Corporation NASDAQ:MNKD | 38.37M | 37.1% | 51.9% | 2.2% | |
![]() Biohaven Ltd. NYSE:BHVN | 0.00 | N/A | N/A | N/A | |
![]() Sionna Therapeutics, Inc. NASDAQ:SION | 0.00 | N/A | N/A | N/A | |
![]() Celldex Therapeutics, Inc. NASDAQ:CLDX | 2.02M | -23.7% | 63.6% | 1.2% | |
![]() Janux Therapeutics, Inc. NASDAQ:JANX | 6.43M | N/A | N/A | N/A | |
![]() Nuvation Bio Inc. NYSE:NUVB | 19.36M | 73.6% | 44.8% | N/A | |
![]() Vera Therapeutics, Inc. NASDAQ:VERA | 3.29M | N/A | N/A | N/A |
Continue your HRMY research with focused valuation guides.
Snapshot
Start with context, operating signals, and key market metrics.
Value Model
Stress test fair value across bear, base, and bull assumptions.
Statements
Validate revenue quality, margins, and balance sheet durability.
Earnings Call
Read management commentary and compare it with reported outcomes.
Dividends
Check payout sustainability and long-term distribution behavior.
Analyst Expectations
Review consensus spread and where estimate risk is concentrated.